Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of MT-2990 in ANCA-associated vasculitis
jRCT2031230538Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of MT-2990 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and 1 more, sponsored by Mitsubishi Tanabe Pharma Corporation. Started Jun 2024; status: completed.
02
Drugs
MT-2990
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT2031230538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230538.